Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia

BACKGROUND: Benign prostatic hyperplasia (BPH) refers to non‐malignant enlargement of the prostate gland that may cause bothersome lower urinary tract symptoms (LUTS). Alpha‐blockers (ABs) and 5‐alpha reductase inhibitors (5‐ARIs) are the mainstay of medical treatment. Recently, phosphodiesterase in...

Full description

Saved in:
Bibliographic Details
Published in:Cochrane Database Syst Rev
Main Authors: Pattanaik, Smita, Mavuduru, Ravimohan S, Panda, Arabind, Mathew, Joseph L, Agarwal, Mayank M, Hwang, Eu Chang, Lyon, Jennifer A, Singh, Shrawan K, Mandal, Arup K
Format: Artigo
Language:Inglês
Published: John Wiley & Sons, Ltd 2018
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6517182/
https://ncbi.nlm.nih.gov/pubmed/30480763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010060.pub2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items